Pharmacies that receive federal funds must provide language support to make sure patients can understand their medication instructions. A survey of 169 outpatient prescribers at a large academic… read more.
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF (320/28.8/10μg)) has been approved in the European Union (EU) as a maintenance treatment for asthma in patients 12… read more.
Lantheus Holdings announced that the FDA has granted final approval for Bravnetsa (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera (lutetium Lu 177 dotatate)…. read more.
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF (320/28.8/10μg)) has been approved in the European Union (EU) as a maintenance treatment for asthma in patients 12… read more.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable… read more.
Nearly a third of the government’s nutrition advisors still have “significant” ties to the food industry including Coca Cola, Sainsbury’s, and Danone, reveals a new analysis by The BMJ today… read more.
Nearly half of health boards in England are deliberately delaying care for patients by imposing minimum waiting times in an attempt to manage demand and control costs, reveals… read more.
Abbott announced FDA authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology. The new biowearable is designed to alert people living with… read more.
Revolution Medicines, Inc. announced that the FDA has approved RASONQUE (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at… read more.
Johnson & Johnson announced the FDA approval of IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults… read more.
Roivant announced that the FDA has approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. DM is… read more.
NICE(UK) updated recommendation their 6 August 2026 recommendation to expand the population in line with the marketing authorisation. We also updated the technology name and title to more… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
